Insider Buying: Electra Therapeutics (NASDAQ:ETRA) Director Acquires $1,141,025.21 in Stock

Posted by Francis Steltz on Nov 8th, 2026

Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Orbimed Advisors Llc purchased 156,091 shares of Electra Therapeutics stock in a transaction dated Thursday, November 5th. The stock was bought at an average cost of $7.31 per share, with a total value of $1,141,025.21. Following the completion of the purchase, the director owned 5,220,762 shares in the company, valued at approximately $38,163,770.22. This trade represents a 3.08% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The stock was bought at an average price of $7.53 per share, with a total value of $537,393.51.
On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The shares were bought at an average price of $7.86 per share, for a total transaction of $1,926,588.18.
On Monday, September 21st, Orbimed Advisors Llc acquired 1,333,333 shares of Electra Therapeutics stock. The shares were bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00.

Electra Therapeutics Trading Up 6.1%

Shares of NASDAQ:ETRA opened at $7.80 on Friday. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ETRA shares. JPMorgan Chase & Co. initiated coverage on Electra Therapeutics in a report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 price objective for the company. Jefferies Financial Group assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 target price on the stock. HC Wainwright initiated coverage on shares of Electra Therapeutics in a research report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Finally, TD Cowen assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Electra Therapeutics has an average rating of “Buy” and a consensus price target of $33.50.

Get Our Latest Stock Report on ETRA

Electra Therapeutics News Summary

Here are the key news stories impacting Electra Therapeutics this week:

Positive Sentiment: OrbiMed Advisors acquired 472,571 shares from November 3–5 for approximately $3.6 million, increasing its reported stake. The repeated purchases are the clearest recent potential positive catalyst for ETRA. Article on insider purchases
Neutral Sentiment: The company is scheduled to present at the Jefferies Global Healthcare Conference on November 18. The appearance could raise its profile, but the announcement did not include new clinical or business updates. Conference announcement

About Electra Therapeutics

(Get Free Report)

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.